HSP90AA1 and metastatic malignant neoplasm: Since MMP inhibitors are in the clinic and Hsp90 inhibitors are awaiting for the clinical appraisal, our study provides novel insights for drug‐resistant metastatic cancer treatment using Hsp90 inhibitors.